Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276639 · ClinicalTrials.gov registry record · Phase 3
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 901
- Enrollment target
- 20
- Study locations
NCT01276639: Completed Phase 3 study of Psoriasis, sponsored by Pfizer.
NCT01276639 is a Phase 3 study of Psoriasis that has completed, run by Pfizer. The registered enrollment target is 901 participants, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01276639, a Phase 3 study of Psoriasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 901 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Primary Outcome
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear;
Conditions Studied
Interventions
- DRUG CP-690,550
- DRUG Placebo/CP-690,550
Study Locations (20)
California
- University of California, Irvine - Dermatology Research - Irvine
- Skin Surgery Medical Group, Inc. - San Diego
- Clinical Science Institute - Santa Monica
Georgia
- Atlanta Dermatology, Vein & Research Center, P.C. - Alpharetta
- Peachtree Dermatology Associates Research Center - Atlanta
- MedaPhase Inc. - Newnan
Florida
- Renstar Medical Research - Ocala
- Academic Alliance in Dermatology - Tampa
Massachusetts
- Tufts Medical Center - Boston
- Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin - Boston
New York
- New York University School of Medicine - New York
- Skin Search of Rochester, Inc. - Rochester
North Carolina
- Raleigh Radiology Blue Ridge - Raleigh
- Wake Research Associates - Raleigh
Alabama
- Radiant Research, Inc. - Birmingham
Colorado
- Cherry Creek Research, Inc. - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT01276639 record still lists
NCT01276639 is an interventional study that assigns participants to a tested intervention. The registered 901 participants enrollment target is mid-sized for trials with a published cap, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which CP-690,550 is the first listed.
NCT01276639 names 20 study sites across 12 states, led by California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT01276639 about?
NCT01276639 is a clinical study titled "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis". The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
What is the current status of trial NCT01276639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2011-03. Estimated completion is 2013-04.
What conditions does trial NCT01276639 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01276639?
The interventions under investigation include: CP-690,550 (DRUG), Placebo/CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01276639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276639 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01276639's enrollment target sits among peer trials
901 13th of 125 higher than 113 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia